XORTX Therapeutics Files June 2025 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Jun 26, 2025 · CIK: 1729214
Sentiment: neutral
Topics: reporting, 6-K
TL;DR
XORTX filed its June 6-K, confirming 20-F annual report filing. Nothing major, just housekeeping.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on June 26, 2025, reporting for the month of June 2025. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. Allen Davidoff, CEO, signed the report.
Why It Matters
This filing provides routine updates for investors regarding XORTX Therapeutics Inc.'s status as a foreign private issuer and its reporting obligations.
Risk Assessment
Risk Level: low — This is a routine filing that does not contain new financial information or significant business developments.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- June 26, 2025 (date) — Filing Date
FAQ
What type of report is XORTX Therapeutics Inc. filing?
XORTX Therapeutics Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
For what period is this report being filed?
This report is filed for the month of June 2025.
Does XORTX Therapeutics Inc. file annual reports under Form 20-F or 40-F?
XORTX Therapeutics Inc. indicates it files annual reports under cover of Form 20-F.
Who signed this Form 6-K filing on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed the Form 6-K filing.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is June 26, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 26, 2025 by Allen Davidoff regarding XORTX Therapeutics Inc. (XRTX).